FDA Lifts Clinical Hold on Pacritinib

5 gennaio 2017 – The FDA has lifted its clinical hold on trials exploring pacritinib, according to CTI BioPharma, the developer of the JAK2/FLT3 inhibitor. In February 2016, the FDA placed a full clinical hold on pacritinib studies following reports of patient deaths related to intracranial hemorrhage, cardiac failure, and cardiac arrest in the phase III PERSIST-2 myelofibrosis trial. To rectify the hold, CTI BioPharma provided the FDA with final clinical study reports from the PERSIST … (leggi tutto)